• Reported GAAP EPS of -$0.16 down -214.29% YoY • Reported revenue of $306.3M up 64.24% YoY • Legend Biotech expects to achieve a company-wide operating profit beyond 2026, supported by its strong balance sheet with $949 million in cash and cash equivalents as of December 31, 2025.
Bullish
Legend Biotech achieved CARVYKTI franchise profitability for FY 2025, treating over 10,000 patients and expanding globally. The company also advanced its pipeline with new candidates and strengthened R&D capabilities.
Bearish
Legend Biotech reported a Q4 2025 net loss of $30.9M, largely due to foreign currency losses, alongside increased selling and administrative expenses. The company also faces patent protection challenges.